Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Go back to Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
(NASDAQ: TVRD) Delayed: 1.79 +0.02 (1.13%)
Previous Close $1.77    52 Week High
Open $1.80    52 Week Low
Day High $1.82    P/E N/A 
Day Low $1.75    EPS
Volume 65,304